PURE Bioscience, Inc.
PURE · OTC
10/31/2025 | 7/31/2025 | 4/30/2025 | 1/31/2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -7.3% | 55.6% | 25.6% | – |
| Cost of Goods Sold | $0 | $1 | $0 | $0 |
| Gross Profit | $0 | $1 | $0 | $0 |
| % Margin | 63.6% | 170,440.4% | 57.6% | 58.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $3 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $4 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -53.5% | -44% | -118.9% | -185.4% |
| Other Income/Exp. Net | -$0 | $0 | $0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -65.5% | -43.5% | -118.1% | -204.1% |
| EPS | -0.004 | -0.003 | -0.005 | -0.007 |
| % Growth | -36.7% | 42.3% | 26.8% | – |
| EPS Diluted | -0.004 | -0.003 | -0.005 | -0.007 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | -$0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -52.1% | -31.8% | -102% | -185.9% |